{"id":"NCT02760368","sponsor":"R-Pharm International, LLC","briefTitle":"Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-19","primaryCompletion":"2018-08","completion":"2018-10","firstPosted":"2016-05-03","resultsPosted":"2020-10-30","lastUpdate":"2023-09-21"},"enrollment":428,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Olokizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm 1: Olokizumab q4w","type":"EXPERIMENTAL"},{"label":"Arm 2: Olokizumab q2w","type":"EXPERIMENTAL"},{"label":"Arm 3: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate (MTX).\n\nThe primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by methotrexate (MTX) therapy.","primaryOutcome":{"measure":"Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response","timeFrame":"at Week 12","effectByArm":[{"arm":"Arm 1: Olokizumab q4w + Methotrexate","deltaMin":100,"sd":null},{"arm":"Arm 2: Olokizumab q2w + Methotrexate","deltaMin":91,"sd":null},{"arm":"Arm 3: Placebo q2w + Methotrexate","deltaMin":37,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":30},"locations":{"siteCount":40,"countries":["Belarus","Bulgaria","Russia"]},"refs":{"pmids":["34344706"],"seeAlso":["http://acrabstracts.org/abstract/safety-and-efficacy-of-olokizumab-in-a-phase-iii-trial-of-patients-with-moderately-to-severely-active-rheumatoid-arthritis-inadequately-controlled-by-methotrexate-credo1-study/","http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=olokizumab&view=1&item=2020OP0021","http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=olokizumab&view=1&item=2020THU0176"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":142},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Leukopenia","White blood cell count decreased","Neutrophil count decreased"]}}